PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (the “Company”) (NASDAQ: PDGI), a leading provider of clinical development services, today reported preliminary net income for the third quarter ended September 30, 2008, of $1.5 million, or $0.08 per diluted share, compared to net income from continuing operations of $6.9 million, or $0.37 per diluted share, in the third quarter 2007.
